148 related articles for article (PubMed ID: 36103180)
1. Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden.
Ventimiglia E; Bill-Axelson A; Bratt O; Montorsi F; Stattin P; Garmo H
JAMA Netw Open; 2022 Sep; 5(9):e2231015. PubMed ID: 36103180
[TBL] [Abstract][Full Text] [Related]
2. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
3. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
4. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
[TBL] [Abstract][Full Text] [Related]
5. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
[TBL] [Abstract][Full Text] [Related]
6. More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.
Eifler JB; Alvarez J; Koyama T; Conwill RM; Ritch CR; Hoffman KE; Resnick MJ; Penson DF; Barocas DA;
J Urol; 2017 Mar; 197(3 Pt 1):614-620. PubMed ID: 27984110
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
8. Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.
Ciccone G; De Luca S; Oderda M; Munoz F; Krengli M; Allis S; Baima CG; Barale M; Bartoncini S; Beldì D; Bellei L; Bellissimo AR; Bernardi D; Biamino G; Billia M; Borsa R; Cante D; Castelli E; Cattaneo G; Centrella D; Collura D; Coppola P; Dalmasso E; Di Stasio A; Fasolis G; Fiorio M; Garibaldi E; Girelli G; Griffa D; Guercio S; Migliari R; Molinaro L; Montefiore F; Montefusco G; Moroni M; Muto G; Ponti di Sant'Angelo F; Ruggiero L; Ruo Redda MG; Serao A; Squeo MS; Stancati S; Surleti D; Varvello F; Volpe A; Zaramella S; Zarrelli G; Zitella A; Bollito E; Gontero P; Porpiglia F; Galassi C; Bertetto O;
JAMA Netw Open; 2023 Oct; 6(10):e2338039. PubMed ID: 37847502
[TBL] [Abstract][Full Text] [Related]
9. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study.
Plym A; Clements M; Voss M; Holmberg L; Stattin P; Lambe M
BMJ Open; 2020 Mar; 10(3):e032914. PubMed ID: 32156761
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
12. Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
BMJ Open; 2019 Dec; 9(12):e033944. PubMed ID: 31874896
[TBL] [Abstract][Full Text] [Related]
13. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
[TBL] [Abstract][Full Text] [Related]
14. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
15. Five-year nationwide follow-up study of active surveillance for prostate cancer.
Loeb S; Folkvaljon Y; Makarov DV; Bratt O; Bill-Axelson A; Stattin P
Eur Urol; 2015 Feb; 67(2):233-8. PubMed ID: 24993868
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
17. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
18. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
[TBL] [Abstract][Full Text] [Related]
19. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
20. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
